Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS

Deep News07-13

Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million.

On July 13th, according to a post on the company's official WeChat account, Insilico Medicine announced a new artificial intelligence-driven drug discovery collaboration with CMS (00867) in the field of central nervous system diseases. The partnership focuses on a high-market-potential indication and is based on a novel mechanism of action identified by the PandaOmics platform.

Under the terms of the agreement, the companies will combine Insilico's validated AI platform and its capabilities in AI-powered innovative drug R&D with CMS's experienced research team and deep understanding of the disease area to jointly advance the collaborative development of the project. Furthermore, Insilico Medicine is eligible to receive milestone payments totaling up to approximately RMB 1.2 billion, along with a share of net sales. This collaboration marks a further deepening of the relationship between the two parties, aiming to fully leverage their complementary strengths across the entire value chain of drug discovery, clinical development, and commercialization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156997423?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156997423","market":"sh","top_or_hot":-1,"title":"Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS","media":"Deep News","content":"<p>Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million.<br><br>\nOn July 13th, according to a post on the company's official WeChat account, Insilico Medicine announced a new artificial intelligence-driven drug discovery collaboration with <b>CMS</b> (<b>00867</b>) in the field of central nervous system diseases. The partnership focuses on a high-market-potential indication and is based on a novel mechanism of action identified by the PandaOmics platform.<br><br>\nUnder the terms of the agreement, the companies will combine Insilico's validated AI platform and its capabilities in AI-powered innovative drug R&D with CMS's experienced research team and deep understanding of the disease area to jointly advance the collaborative development of the project. Furthermore, Insilico Medicine is eligible to receive milestone payments totaling up to approximately RMB 1.2 billion, along with a share of net sales. This collaboration marks a further deepening of the relationship between the two parties, aiming to fully leverage their complementary strengths across the entire value chain of drug discovery, clinical development, and commercialization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-13 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million.<br><br>\nOn July 13th, according to a post on the company's official WeChat account, Insilico Medicine announced a new artificial intelligence-driven drug discovery collaboration with <b>CMS</b> (<b>00867</b>) in the field of central nervous system diseases. The partnership focuses on a high-market-potential indication and is based on a novel mechanism of action identified by the PandaOmics platform.<br><br>\nUnder the terms of the agreement, the companies will combine Insilico's validated AI platform and its capabilities in AI-powered innovative drug R&D with CMS's experienced research team and deep understanding of the disease area to jointly advance the collaborative development of the project. Furthermore, Insilico Medicine is eligible to receive milestone payments totaling up to approximately RMB 1.2 billion, along with a share of net sales. This collaboration marks a further deepening of the relationship between the two parties, aiming to fully leverage their complementary strengths across the entire value chain of drug discovery, clinical development, and commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"","article_id":"1156997423","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156997423","pubTimestamp":1783908642,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million. On July 13th, according to a post on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","QTOC":"Innovator Growth Accelerated Plus ETF - October","AIPO":"Defiance AI and Power Infrastructure ETF","WRND":"NYLI Global Equity R&D Leaders ETF","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","BK4588":"碎股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","GSKH":"GSK plc ADRhedged","00867":"康哲药业","AGIX":"通用人工智能 ETF-AGIX","SBIO":"ALPS Medical Breakthroughs ETF","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK1191":"制药","SG9999015978.USD":"利安颠覆性创新基金A","BK1593":"医美概念股","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BBP":"Virtus LifeSci Biotech Products ETF","VTHR":"Vanguard Russell 3000 ETF","BK4585":"ETF&股票定投概念","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","GDOC":"Goldman Sachs Future Health Care Equity ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF"},"translate_title":"Insilico Medicine 与 CMS 建立新的人工智能药物发现合作伙伴关系，早盘交易中股价飙升超过 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WRND":1,"AIPO":1,"GSKH":1,"ARTY":1,"VTHR":1,"IBB":1,"AGIX":1,"SBIO":1,"QTOC":1,"LFSC":1,"CHAT":1,"PBE":1,"GDOC":1,"BBP":1,"00867":1},"content_text":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million.\nOn July 13th, according to a post on the company's official WeChat account, Insilico Medicine announced a new artificial intelligence-driven drug discovery collaboration with CMS (00867) in the field of central nervous system diseases. The partnership focuses on a high-market-potential indication and is based on a novel mechanism of action identified by the PandaOmics platform.\nUnder the terms of the agreement, the companies will combine Insilico's validated AI platform and its capabilities in AI-powered innovative drug R&D with CMS's experienced research team and deep understanding of the disease area to jointly advance the collaborative development of the project. Furthermore, Insilico Medicine is eligible to receive milestone payments totaling up to approximately RMB 1.2 billion, along with a share of net sales. This collaboration marks a further deepening of the relationship between the two parties, aiming to fully leverage their complementary strengths across the entire value chain of drug discovery, clinical development, and commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156997423","isCrawlerRequest":true}